Testing a new medication for blood cancer that has returned after previous treatment

This study is testing a new medication called olutasidenib for people with acute myeloid leukemia (a serious blood cancer) that has returned or stopped responding to previous treatment—specifically, treatment that included a drug called venetoclax. The medication works by targeting a specific genetic mutation (IDH1) that drives this type of cancer. Researchers want to see how many people improve with this treatment and whether adding a second medication might help those who don't respond well enough.

Some people with this type of blood cancer stop responding to venetoclax-based treatment, leaving them with few options. This trial exists to see if this medication, which targets the underlying genetic cause of their cancer, can help people whose cancer has become resistant to their previous treatments.